尚小珂,陈澍,董念国,钟良,王斌,朱达,宋光远,廖曼,张长东

• 1:华中科技大学同济医学院附属协和医院心脏大血管外科
• 2:新加坡中央医院国家心脏中心心脏动力实验室
• 3:四川大学华西医院心脏外科
• 4:国家心血管病中心北京协和医学院中国医学科学院阜外医院结构性心脏病中心

摘要(Abstract)：

<正>心力衰竭是各种慢性结构性或非结构性心脏病发展到后期的共同表现。美国现有620万例心力衰竭患者群体,并且由于人口老龄化的不断进展发病率持续增加[1]。针对这些患者的不良预后,已经有许多控制心力衰竭进展和提高心力衰竭患者生存率的治疗方法。近几年,在指南的规范药物治疗下开始出现一些辅助器械治疗(例如心脏再同步疗法、植入式监测器、心室辅助装置)和心脏移植等[2]。尽管如此,还需要进一步研发新的心力衰竭器械,以解决目前仍然较高的患者死亡率(高危亚组每年20%～25%)和大量的心力衰竭住院率(美国每年>100万人次)[1]。心房分流术是一种治疗心力衰竭的新方法。对于许多患者

关键词(KeyWords)： 心力衰竭;房间隔;分流器;左心房压力;左心前负荷

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81570325);; 湖北省卫健委创新基金(WJ2019M173);; 国家重点研发计划(2016YFA0101100)

作者(Author): 尚小珂,陈澍,董念国,钟良,王斌,朱达,宋光远,廖曼,张长东

参考文献(References)：

• [1] Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019ACC expert consensus decision pathway on risk assessment,management, and clinical trajectory of patients hospitalized with heart failure:A report of the American College of Cardiology Solution Set Oversighe Committee. J Am Coll Cardiol, 2019,74(15):1966-2011.
• [2]邹彤，杨杰孚.慢性心力衰竭的植入性器械治疗进展.中国介入心脏病学杂志，2016,24(12):692-695.
• [3] Lim GB. Device therapy:Interatrial shunt device for HFpEF. Nat Rev Cardiol, 2018, 15(1):4.
• [4] Wessler J, Kaye D, Gustafsson F, et al. Impact of baseline hemodynamics on the effects of a transcatheter interatrial shunt device in heart failure with preserved ejection fraction. Circ Heart Fail, 2018, 11(8):e004540.
• [5] Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial. JAMA, 2013, 309(12):1268-1277.
• [6] Sambhi MP, Zimmerman HA. Pathologic physiology of Lutembacher syndrome. Am J Cardiol,1958,2(6):681-686.
• [7] Dorfs S, Zeh W, Hochholzer W, et al. Pulmonary capillary wedge pressure dur-ing exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J,2014, 35(44):3103-3112.
• [8] Paitazoglou C，?zdemir R, P?ster R, et al. The AFR-PRELIEVE trial:a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator(AFR)in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention, 2019, 15(5):403-410.
• [9] Andersen MJ, Ersb?ll M, Gustafsson F, et al. Exercise-induced changes in left ventricular?lling pressure after myocardial infarction assessed with simultaneous right heart catheterization and Doppler echocardiography. Int J Cardiol, 2013, 168(3):2803-2810.
• [10] Kaye D, Shah SJ, Borlaug BA, et al. Eff ects of an interatrial shunt on rest and exercise hemodynamics:results of a computer simulation in heart failure. J Card Fail, 2014, 20(3):212-221.
• [11] S?ndergaard L, Reddy V, Kaye D, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail, 2014, 16(7):796-801.
• [12] Kaye DM, Hasenfu?G, Neuzil P, et al. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail, 2016, 9(12):e003662.
• [13] Kaye DM, Petrie MC, Mckenzie S, et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 2019, 6(1):62-69.
• [14] Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction[REDUCE LAP-HF I(Reduce Elevated Left Atrial Pressure in Patients With Heart Failure)]:a phase 2, randomized, shamcontrolled trial. Circulation, 2018, 137(4):364-375.
• [15] Amat-Santos IJ, Del Trigo M, Bergeron S, et al. Left atrial decompression using unidirectional left-to-right interatrial shunt:initial experience in treating symptomatic heart failure with preserved ejection fraction with the V-Wave device. JACC Cardiovasc Interv,2015, 8(6):870-872.
• [16] Amat-Santos IJ, Bergeron S, Bernier M, et al. Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure:First-in-man experience with the V-Wave device. EuroIntervention, 2015, 10(9):1127-1131.
• [17] Del Trigo M, Bergeron S, Bernier M, et al. Unidirectional left-toright interatrial shunting for treatment of patients with heart failure with reduced ejection fraction:a safety and proof-of-principle cohort study. Lancet, 2016, 387(10025):1290-1297.
• [18] Rodés-Cabau J, Bernier M, Amat-Santos IJ, et al. Interatrial shunting for heart failure:early and late results from the first-inhuman experience with the V-Wave system. JACC Cardiovasc Interv, 2018, 11(22):2300-2310.
• [19] Guimar?es L, Bergeron S, Bernier M, et al. Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure. EuroIntervention, 2020,15(16):1426-1428.
• [20] Patel MB, Samuel BP, Girgis RE, et al. Implantable atrial?ow regulator for severe, irreversible pulmonary arterial hypertension.Euro Intervention, 2015, 11(6):706-709.
• [21] Rajeshkumar R, Pavithran S, Sivakumar K, et al. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension. Catheter Cardiovasc Interv,2017, 90(7):1145-1153.
• [22] Manuri L, Calaciura RE, De Zorzi A, et al. Atrial?ow regulator for failing Fontan circulation:an initial European experience. Interact Cardiovasc Thorac Surg, 2018, 27(5):761-764.
• [23]刘燕青，周欣蓓，蔡尚郎.心房分流术治疗慢性心力衰竭的研究进展.中国介入心脏病学杂志，2019,27(9):526-528.